Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting

Angelis, Aris; Montibeller, Gilberto; Hochhauser, Daniel; Kanavos, Panos

doi:10.1186/s12911-017-0524-3

BMC Medical Informatics and Decision Making

Table 1 Attributes definition and sources of evidence

From: Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting

Cluster	Attribute	Definition	Evidence source
			Aflibercept + FOLFIRI	Cetuximab	Panitumumab
Therapeutic Impact	Overall survival	The median time from treatment randomisation to death	Van Cutsem et al. 2012 [32]	Price et al. 2014 [33]	Price et al. 2014
	HRQoL	Health related quality of life using EQ-5D score	TA 307 [22]	Hoyle et al. 2013 [35]	Hoyle et al. 2013
	Progression free survival	The median survival time during which patients have not experienced disease progression (using RECIST criteria)	Van Cutsem et al. 2012	Price et al. 2014 [33]	Price et al. 2014
	Objective response rate	The proportion of patients that experience complete response and partial response (using RECIST criteria)	Van Cutsem et al. 2012	Price et al. 2014	Price et al. 2014
Safety Profile	Grade 3 AEs	The proportion of patients experiencing a Grade 3 adverse event	Van Cutsem et al. 2012	Price et al. 2014	Price et al. 2014
	Grade 4 AEs	The proportion of patients experiencing a Grade 4 adverse event	Van Cutsem et al. 2012	Price et al. 2014	Price et al. 2014
	Contra-indications	The existence of any type of contraindication accompanying the treatment	EPAR [39], Prescribing info	EPAR [37], Prescribing info	EPAR [38], Prescribing info
Innovation Level	ATC Level 1	The technology’s relative market entrance in regards to its ATC Level 1 (Anatomical)	WHO ATC index [40]	WHO ATC index	WHO ATC index
	ATC Level 2	The technology’s relative market entrance in regards to its ATC Level 2 (Therapeutic)	WHO ATC index	WHO ATC index	WHO ATC index
	ATC Level 3	The technology’s relative market entrance in regards to its ATC Level 3 (Pharmacological)	WHO ATC index	WHO ATC index	WHO ATC index
	ATC Level 4	The technology’s relative market entrance in regards to its ATC Level 4 (Chemical)	WHO ATC index	WHO ATC index	WHO ATC index
	ATC Level 5	The technology’s relative market entrance in regards to its ATC Level 5 (Molecular)	WHO ATC index	WHO ATC index	WHO ATC index
	Phase 1	The number of new indications for which the technology is investigated in Phase 1 clinical trials	ClinicalTrials.gov [41]	ClinicalTrials.gov	ClinicalTrials.gov
	Phase 2	The number of new indications for which the technology is investigated in Phase 2 clinical trials	ClinicalTrials.gov	ClinicalTrials.gov	ClinicalTrials.gov
	Phase 3	The number of new indications for which the technology is investigated in Phase 3 clinical trials	ClinicalTrials.gov	ClinicalTrials.gov	ClinicalTrials.gov
	Marketing authorisation	The number of new indications for which the technology has gained a marketing authorisation approval	ClinicalTrials.gov	ClinicalTrials.gov	ClinicalTrials.gov
	Posology	The frequency of doses in a given time period in combination with the duration of the administration	EPAR, Prescribing info	EPAR, Prescribing info	EPAR, Prescribing info
Socio-economic Impact	Medical costs impact	The impact of the technology on direct medical costs excluding the purchasing costs of the technology	BNF 69, TA 307, Wade et al. 2013 [34]	BNF 69, TA 242 [21], Hoyle et al. 2013	BNF 69, TA 242, Hoyle et al. 2013

Back to article page

ISSN: 1472-6947

Contact us

General enquiries: journalsubmissions@springernature.com